Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$33.70
0.000.00%
Pre-Market: 4:00 PM EDT
Comments
Loading...
Kymera Therapeutics Analyst Ratings and Price Targets | NASDAQ:KYMR | Benzinga
Kymera Therapeutics Inc has a consensus price target of $51.04 based on the ratings of 25 analysts. The high is $74 issued by UBS on November 4, 2024. The low is $30 issued by B of A Securities on January 3, 2024. The 3 most-recent analyst ratings were released by Citigroup, HC Wainwright & Co., and Stephens & Co. on March 13, 2025, February 28, 2025, and January 21, 2025, respectively. With an average price target of $57.33 between Citigroup, HC Wainwright & Co., and Stephens & Co., there's an implied 70.13% upside for Kymera Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
HC Wainwright & Co.
Stephens & Co.
Leerink Partners
BTIG
1calculated from analyst ratings
Analyst Ratings for Kymera Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/13/2025 | Buy Now | 54.3% | Citigroup | Geoff Meacham63% | → $52 | Initiates | → Buy | Get Alert |
| 02/28/2025 | Buy Now | 78.04% | HC Wainwright & Co. | Andrew Fein57% | $54 → $60 | Maintains | Buy | Get Alert |
| 01/21/2025 | Buy Now | 78.04% | Stephens & Co. | Sudan Loganathan32% | $60 → $60 | Reiterates | Overweight → Overweight | Get Alert |
| 12/27/2024 | Buy Now | 78.04% | Leerink Partners | Faisal Khurshid32% | $60 → $60 | Maintains | Outperform | Get Alert |
| 12/10/2024 | Buy Now | 78.04% | BTIG | Jeet Mukherjee 8% | → $60 | Initiates | → Buy | Get Alert |
| 12/06/2024 | Buy Now | 63.2% | BMO Capital | Etzer Darout50% | → $55 | Initiates | → Market Perform | Get Alert |
| 12/02/2024 | Buy Now | 69.14% | Wells Fargo | Derek Archila59% | $38 → $57 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 11/18/2024 | Buy Now | 92.88% | Stephens & Co. | Sudan Loganathan32% | → $65 | Initiates | → Overweight | Get Alert |
| 11/06/2024 | Buy Now | 45.4% | Morgan Stanley | James Quigley26% | $45 → $49 | Maintains | Equal-Weight | Get Alert |
| 11/04/2024 | Buy Now | 119.58% | UBS | Eliana Merle46% | $80 → $74 | Maintains | Buy | Get Alert |
| 11/01/2024 | Buy Now | 54.3% | Guggenheim | — | $45 → $52 | Maintains | Buy | Get Alert |
| 11/01/2024 | Buy Now | 57.27% | Truist Securities | Srikripa Devarakonda47% | $54 → $53 | Reiterates | Buy → Buy | Get Alert |
| 09/27/2024 | Buy Now | 66.17% | Oppenheimer | Jeff Jones32% | $52 → $56 | Maintains | Outperform | Get Alert |
| 09/09/2024 | Buy Now | 78.04% | Leerink Partners | Faisal Khurshid32% | → $60 | Assumes | → Outperform | Get Alert |
| 08/26/2024 | Buy Now | 92.88% | Wolfe Research | Andy Chen39% | → $65 | Upgrade | Peer Perform → Outperform | Get Alert |
| 08/14/2024 | Buy Now | 33.53% | Morgan Stanley | James Quigley26% | $34 → $45 | Maintains | Equal-Weight | Get Alert |
| 08/12/2024 | Buy Now | 12.76% | Wells Fargo | Derek Archila59% | $30 → $38 | Maintains | Equal-Weight | Get Alert |
| 07/10/2024 | Buy Now | 54.3% | Oppenheimer | Jeff Jones32% | $52 → $52 | Maintains | Outperform | Get Alert |
| 07/09/2024 | Buy Now | 6.82% | B. Riley Securities | Kalpit Patel40% | $31 → $36 | Maintains | Neutral | Get Alert |
| 06/17/2024 | Buy Now | 36.5% | HC Wainwright & Co. | Andrew Fein57% | $46 → $46 | Reiterates | Buy → Buy | Get Alert |
| 06/03/2024 | Buy Now | 36.5% | HC Wainwright & Co. | Andrew Fein57% | $46 → $46 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2024 | Buy Now | 36.5% | HC Wainwright & Co. | Andrew Fein57% | $46 → $30 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2024 | Buy Now | 54.3% | Oppenheimer | Jeff Jones32% | $53 → $52 | Maintains | Outperform | Get Alert |
| 04/22/2024 | Buy Now | 57.27% | Oppenheimer | Jeff Jones32% | → $53 | Initiates | → Outperform | Get Alert |
| 03/01/2024 | Buy Now | 60.24% | Truist Securities | Srikripa Devarakonda47% | $41 → $54 | Maintains | Buy | Get Alert |
| 02/27/2024 | Buy Now | 66.17% | Piper Sandler | Edward Tenthoff52% | $39 → $56 | Maintains | Overweight | Get Alert |
| 02/23/2024 | Buy Now | 39.47% | JP Morgan | Eric Joseph47% | $34 → $47 | Maintains | Overweight | Get Alert |
| 02/23/2024 | Buy Now | 63.2% | Stifel | Bradley Canino40% | $35 → $55 | Maintains | Buy | Get Alert |
| 02/15/2024 | Buy Now | — | Wolfe Research | Andy Chen39% | — | Initiates | → Peer Perform | Get Alert |
| 01/03/2024 | Buy Now | -10.98% | B of A Securities | Geoff Meacham63% | $45 → $30 | Downgrade | Buy → Neutral | Get Alert |
| 12/19/2023 | Buy Now | -22.85% | Wells Fargo | Derek Archila59% | → $26 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/13/2023 | Buy Now | -28.78% | Morgan Stanley | James Quigley26% | $37 → $24 | Maintains | Equal-Weight | Get Alert |
| 11/03/2023 | Buy Now | 12.76% | Piper Sandler | Edward Tenthoff52% | $58 → $38 | Maintains | Overweight | Get Alert |
| 11/03/2023 | Buy Now | -10.98% | HC Wainwright & Co. | Andrew Fein57% | $85 → $30 | Maintains | Buy | Get Alert |
| 08/29/2023 | Buy Now | 9.79% | Morgan Stanley | James Quigley26% | $39 → $37 | Maintains | Equal-Weight | Get Alert |
| 08/07/2023 | Buy Now | 54.3% | Stifel | Bradley Canino40% | $48 → $52 | Maintains | Buy | Get Alert |
| 08/04/2023 | Buy Now | 9.79% | Credit Suisse | Richard Law45% | $36 → $37 | Maintains | Neutral | Get Alert |
| 08/04/2023 | Buy Now | 152.23% | HC Wainwright & Co. | Andrew Fein57% | → $85 | Reiterates | Buy → Buy | Get Alert |
| 06/30/2023 | Buy Now | 48.37% | Truist Securities | Srikripa Devarakonda47% | → $50 | Initiates | → Buy | Get Alert |
| 06/15/2023 | Buy Now | 42.43% | Stifel | Bradley Canino40% | → $48 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2023 | Buy Now | 6.82% | Credit Suisse | Richard Law45% | → $36 | Reiterates | Neutral → Neutral | Get Alert |
| 05/09/2023 | Buy Now | 15.73% | Morgan Stanley | James Quigley26% | $41 → $39 | Maintains | Equal-Weight | Get Alert |
| 05/05/2023 | Buy Now | 6.82% | Credit Suisse | Richard Law45% | $39 → $36 | Maintains | Neutral | Get Alert |
| 05/05/2023 | Buy Now | 12.76% | Raymond James | Steven Seedhouse58% | → $38 | Upgrade | Market Perform → Outperform | Get Alert |
| 02/24/2023 | Buy Now | 15.73% | Credit Suisse | Richard Law45% | $32 → $39 | Maintains | Neutral | Get Alert |
| 02/24/2023 | Buy Now | 152.23% | HC Wainwright & Co. | Andrew Fein57% | → $85 | Reiterates | → Buy | Get Alert |
| 01/03/2023 | Buy Now | 24.63% | Wells Fargo | Derek Archila59% | $40 → $42 | Maintains | Overweight | Get Alert |
| 12/19/2022 | Buy Now | 21.66% | Morgan Stanley | Vikram Purohit38% | $38 → $41 | Maintains | Equal-Weight | Get Alert |
| 12/16/2022 | Buy Now | 54.3% | Goldman Sachs | Chris Shibutani54% | $40 → $52 | Maintains | Buy | Get Alert |
| 12/15/2022 | Buy Now | -8.01% | SVB Leerink | Mike Kratky66% | $26 → $31 | Maintains | Market Perform | Get Alert |
| 12/06/2022 | Buy Now | -5.04% | Credit Suisse | Richard Law45% | $47 → $32 | Downgrade | Outperform → Neutral | Get Alert |
| 11/08/2022 | Buy Now | 6.82% | Wells Fargo | Derek Archila59% | $35 → $36 | Maintains | Overweight | Get Alert |
| 11/08/2022 | Buy Now | — | Raymond James | Steven Seedhouse58% | — | Initiates | → Market Perform | Get Alert |
| 11/04/2022 | Buy Now | 12.76% | Morgan Stanley | Vikram Purohit38% | $37 → $38 | Maintains | Equal-Weight | Get Alert |
| 11/04/2022 | Buy Now | 39.47% | Credit Suisse | Richard Law45% | $61 → $47 | Maintains | Outperform | Get Alert |
| 08/29/2022 | Buy Now | 9.79% | Morgan Stanley | Vikram Purohit38% | $35 → $37 | Maintains | Equal-Weight | Get Alert |
| 08/15/2022 | Buy Now | 18.69% | Jefferies | Kelly Shi41% | → $40 | Initiates | → Buy | Get Alert |
| 08/10/2022 | Buy Now | 81.01% | Credit Suisse | Richard Law45% | $60 → $61 | Maintains | Outperform | Get Alert |
| 08/03/2022 | Buy Now | 18.69% | Goldman Sachs | Chris Shibutani54% | → $40 | Initiates | → Buy | Get Alert |
| 07/20/2022 | Buy Now | -22.85% | SVB Leerink | Mike Kratky66% | → $26 | Initiates | → Market Perform | Get Alert |
| 06/01/2022 | Buy Now | 3.86% | Wells Fargo | Derek Archila59% | $62 → $35 | Maintains | Overweight | Get Alert |
| 05/23/2022 | Buy Now | 27.6% | Piper Sandler | Edward Tenthoff52% | $91 → $43 | Maintains | Overweight | Get Alert |
| 05/04/2022 | Buy Now | 3.86% | Morgan Stanley | Vikram Purohit38% | $66 → $35 | Maintains | Equal-Weight | Get Alert |
| 05/04/2022 | Buy Now | 78.04% | Credit Suisse | — | $63 → $60 | Maintains | Outperform | Get Alert |
| 04/28/2022 | Buy Now | 86.94% | Credit Suisse | Richard Law45% | → $63 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Kymera Therapeutics (KYMR) stock?
The latest price target for Kymera Therapeutics (NASDAQ:KYMR) was reported by Citigroup on March 13, 2025. The analyst firm set a price target for $52.00 expecting KYMR to rise to within 12 months (a possible 54.30% upside). 24 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kymera Therapeutics (KYMR)?
The latest analyst rating for Kymera Therapeutics (NASDAQ:KYMR) was provided by Citigroup, and Kymera Therapeutics initiated their buy rating.
When was the last upgrade for Kymera Therapeutics (KYMR)?
The last upgrade for Kymera Therapeutics Inc happened on December 2, 2024 when Wells Fargo raised their price target to $57. Wells Fargo previously had an equal-weight for Kymera Therapeutics Inc.
When was the last downgrade for Kymera Therapeutics (KYMR)?
The last downgrade for Kymera Therapeutics Inc happened on January 3, 2024 when B of A Securities changed their price target from $45 to $30 for Kymera Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Kymera Therapeutics (KYMR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kymera Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kymera Therapeutics was filed on March 13, 2025 so you should expect the next rating to be made available sometime around March 13, 2026.
Is the Analyst Rating Kymera Therapeutics (KYMR) correct?
While ratings are subjective and will change, the latest Kymera Therapeutics (KYMR) rating was a initiated with a price target of $0.00 to $52.00. The current price Kymera Therapeutics (KYMR) is trading at is $33.70, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.